Sveva GERMINI – *CV*

Sveva Germini graduated in Chemistry in 2022 at University of Rome Tor Vergata. She is currently pursuing her PhD degree in System and Experimental Medicine at two institutions: University of Rome Tor Vergata and Italian National Institute of Health (ISS), under the supervision of Dr. Serena Camerini, Dr. Marialuisa Casella and prof. Rossella Menghini. In this project, she develops mass spectrometry (MS)-based proteomics approaches to understand how the proteome of triple negative breast cancer cells is affected by the anti-diabetic drug Metformin, the inhibitor D609, or their combination. In 2021 she joined the nuclear magnetic resonance (NMR) laboratory at University of Rome Tor Vergata to work on her master's thesis under the supervision of prof. Daniel Oscar Cicero and prof. Greta Petrella. With a NMR-based exometabolomics approach, she studied the metabolic pathways involved in the chemoresistance induced in castration-resistant prostate cancer cells by Etoposide.